Prancer RTSM vs Suvoda RTSM(RTSM / IRT)

Sponsors and CROs choosing a randomization and trial supply management (RTSM, also called IRT) system for interventional trials.

Scope Sponsors and CROs choosing an RTSM/IRT system to randomize participants and manage investigational product supply in interventional trials. Site-side pharmacy tools and stand-alone supply planning software are out of scope.

Guide updated How we compare

Compare within RTSM / IRT

Study fit, side by side

These notes describe the products in the RTSM / IRT guide.

Prancer RTSM

Best for
Sponsors and CROs with complex dosing or adaptive designs who want an RTSM specialist with supply forecasting
What to consider
4G Clinical is an RTSM specialist: Prancer covers randomization, resupply and direct-to-patient shipping, and 4C Supply adds portfolio-level forecasting. It publishes a SOC 2 Type 2 report and a Part 11 statement, and says it has supported more than 1,000 studies. It has no EDC or eCOA of its own, so plan for integrations.
Read product profile

Suvoda RTSM

Best for
Oncology, CNS and rare disease sponsors who want IRT alongside eCOA, eConsent and patient payments on one platform
What to consider
Suvoda runs its RTSM on one platform with eCOA, eConsent and Greenphire patient payments, and offers pre-built API integrations with major EDCs. It publishes the shortest build claim on this list (kickoff to UAT in as little as two weeks, footnoted as preliminary testing) and an annual SOC 2 Type 2 audit for RTSM. Its public pages name stratification and adaptive designs but not minimization.
Read product profile

Compare the features

Both products use the same category definitions. Product order is editorial; products are not ranked.

Full RTSM / IRT feature comparison

Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.

Expand a feature definition or support note for context and its original source.

Prancer RTSM vs Suvoda RTSM (RTSM / IRT): category feature evidence and sources. Products are not ranked.
Category featurePrancer RTSMSuvoda RTSM
Randomization and blinding
Feature definitions
Supported
Randomization or blinding workflows are stated.
Extended support
Named allocation methods include minimization or dynamic allocation.
Extended support

4G names stratification, cohort-specific logic, variable blocks and minimization, with versioned logic that protects blinding and handles re-randomization.

Source
About this support label

Named methods include variable blocks and minimization with blinding protection.

Supported

Suvoda lists adaptive randomization, stratification, cohort and dose management and blinding management, but its public pages do not name minimization or dynamic allocation.

Source
About this support label

Adaptive and stratified randomization are stated; minimization or dynamic allocation is not named.

Trial supply management
Feature definitions
Supported
Drug inventory, dispensing, shipping or resupply workflows are documented.
Extended support
Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
Extended support

Prancer handles dispensing and resupply with buffer-to-predictive forecasting and 4C Supply scenario modeling; direct-to-patient shipping was added in April 2020 (4G blog).

Source
About this support label

Predictive resupply, scenario modeling and direct-to-patient shipping are stated.

Extended support

The RTSM page lists drug supply forecasting, direct-to-patient shipping, temperature excursion management, and accountability, returns and destruction.

Source
About this support label

Drug forecasting and direct-to-patient shipping are both named.

Study build speed and mid-study changes
Feature definitions
Supported
Study setup or post-go-live study changes are described.
Extended support
Study setup is described, and post-go-live changes explicitly avoid interrupting live study use.
Supported

4G says its NLP-based build takes under four weeks, with specification sign-off to go-live in as little as 13 calendar days, and changes made without impacting study progress.

Source
About this support label

A build timeline and changes protecting study progress are stated; uninterrupted live use is not explicit.

Supported

Suvoda states kickoff to UAT in as little as two weeks (footnoted as preliminary testing), and permissioned users can make common post-go-live changes without a change order.

Source
About this support label

The UAT timeline concerns preliminary testing; permissioned changes do not establish uninterrupted live use.

Integrations and platform
Feature definitions
Supported
Integration or data exchange with another system or application is described.
Extended support
Integration with a clinical-trial application plus an API for integration are both stated.
Supported

4G documents connections to EDC, CTMS, depot and logistics systems and data warehouses, but has no EDC or eCOA of its own and we found no public API reference.

Source
About this support label

Connections to trial systems establish base support; a public API reference was not found.

Extended support

Suvoda reports integrations with more than 100 eClinical systems, standardized pre-built API integrations with top EDC providers and a REST API.

Source
About this support label

Pre-built EDC API integrations and a REST API are stated.

Compliance and security evidence
Feature definitions
Supported
Relevant trial compliance or security controls are stated, with their scope identified.
Extended support
Relevant trial controls and a publicly accessible ISO certificate or SOC audit report covering the product or vendor are documented.
Supported

The trust center reports a SOC 2 Type 2 report for the 12 months ending 31 August 2026 and states compliance with 21 CFR Part 11 and EU Annex 11.

Source
About this support label

Trial standards and a dated SOC report period are stated; public report access is not established.

Supported

Suvoda says its RTSM adheres to 21 CFR Part 11 and that it maintains SOC 2 Type 2 compliance; its certifications page confirms an annual SOC 2 Type 2 audit for RTSM.

Source
About this support label

RTSM trial controls and an annual SOC audit are stated; public report access is not established.

Track record
Feature definitions
Supported
Published product or wider-platform adoption, or a named clinical-research deployment.
Extended support
Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Supported

4G says it has evolved to support more than a thousand studies worldwide.

Source
About this support label

Study adoption is reported worldwide, but no country count is given.

Extended support

Suvoda reports 6,000+ trials and 115+ countries supported.

Source
About this support label

Product-specific trial adoption is reported across a stated country count.

The guide update date reflects guide edits. Vendor statements are attributed in the evidence.

Keep the category in view

Compare these products with the other tools in the RTSM / IRT guide using the same feature definitions.

More RTSM / IRT comparisons featuring one of these products.